BioAge Labs

BioAge Labs is a biotechnology company focused on developing novel therapies for metabolic diseases by harnessing the biology of human aging. Their lead program, Azelaprag, aims to be a groundbreaking oral weight-loss therapy that can be co-administered with incretin drugs to mimic the weight loss effects of injectables. The company utilizes a proprietary human-first discovery platform that analyzes multi-omics data to identify molecular mediators of aging and disease, targeting key pathways involved in metabolic aging.